The need for sample size calculations is briefly reviewed: many of the arguments against small trials are already wel known, and we only cursorily repeat them in passing. Problems (Machin and Campbell, 1987) . This indicates that, if R2 does improve survival by 14%, we would be 90% certain of obtaining a signifi level of P<0.05; conversely, 10% of the time we would fail to obtain a 'sificant' P-value (P not less than 5%), despite R2 being 14% better than RI. Sometimes this is described as a 10% false-negative rate. If
by chance alone less than 5% of the time, and so it is quite likely that a treatment difference really is present.
However, if only a few patients were entered into the trial then, even if there really is a true treatment difference, the results are likely to be less convincing than if a much largr number of patients had been assessed. Thus, the weight of evidence in favour of concluding that there is a treatment effect will be much less in a small trial than in a large one. In particular, if a clinical trial is too small it will be unlikely that one will obtain sufficiently convincing evidence of a treatment difference, even when there really is a difference in efficacy of the treatments; small trials frequently conclude 'there was no significant difference', ir ive of whether there really is a treatment effect or not. In statistical terms, we would say that the 'sample size' is too small and that the 'power of the test' is very low. The (RI) , as widely practised in the West, with radical surgery including extended lymph node dissection (R2), which is commonly practised in Japan. The principal end point of interest was survival; reports from Japan showed that patients undergoing R2 surgery had appreciably longer survival durations than those experienced by patients in other countries, and attributed the difference to the surgery. Since R2 surgery is far more extensive and aggressive than RI, increased post-operative morbidity and possibly mortality would have to be offset by reasonably lar survival advantages for R2 to be worthwhile.
Based upon past experience, it was estimated that the baseline survival rate of patients undergoing an RI resection would be 20% at 5 years. The surgeons also thought that R2 surgery might offer appreciable benefits, and a 14% improvement, to 34%, was thought realistic and worthwhile. It was decded that a P-value of P<0.05 would be an acceptable 'significance level' for the test. Thus, if a P-vahle of P<0.05 were obtained, we would be able to declare that such extreme data are unlilkely to be due to chance, and that we believe there really is a treatment difference due to surgery; to be more precise, we would only expect such extreme results in one trial out of 20 (5%) purely by chance, and thus we would assume that R2 is more effective than RI.
Calculations show that 400 patients (185 per treatment arm, which was rounded up to 200) are required for a 90% power (Machin and Campbell, 1987) . This indicates that, if R2 does improve survival by 14%, we would be 90% certain of obtaining a signifi level of P<0.05; conversely, 10% of the time we would fail to obtain a 'sificant' P-value (P not less than 5%), despite R2 being 14% better than RI. Sometimes this is described as a 10% false-negative rate. If fewer patients were entered. we would be less likely to obtain a 5% P-value; thus 200 patients (100 per arm) would provide a power of 66%. In such circumstances, one-third of such trials could be expected to yield false-negative results. Such a low power is generally regarded as unacceptable. In most contexts, 80% is a realistic lower limit for power.
In However, Freiman et al. showed that half of these trials had a power of less than 60% to detect a therapeutic benefit as large as 50%. They commented 'The conclusion is inescapable that many of the therapies discarded as ineffective after inconclusive 'negative' trials may still have a clinically meaningful effect '. Yusut et al. (1984) . in a paper entitled 'Why do we need some large and simple randomised trials?'. argued that for many new treatments, in many disease areas, it is only plausible to anticipate at best a relative mortality reduction of 15%; furthermore, especially in common diseases. even such modest mortality reductions are worth detecting since they imply the saving of many lives. Results from cancer trials over the decade since that paper strongly support the conclusion that in cancer, too, a major treatment breakthrough is frequently little more than a dream. The reality is that most therapeutic advances represent small steps, although collectively they may contribute to a larger overall improvement in survival. Few trials have demonstrated a mortality reduction as large as 15%.
Yusuf et al. also showed that the implication of this is that frequently trials ought to aim to enter many thousands of patients, and that even 2000 may be inadequate, although 'in real life, of course, the situation is even worse than this, as the average trial size is probably nearer to 200 than to 2000 patients!'. However, it is important to note that their paper relates to 'large, simple randomized trials of the effects on mortality of various widelv practicable treatments for common conditions'. This is often overlooked, although Freedman (1989) Goodman and Berlin (1994) , 'Although several writers have pointed out the error implicit in the concept of post hoc power. such caveats have not had great impact'. The issues involved are subtle and rather complex, and to some extent remain controversial. The principal is that, whilst power calculations are vital to the design of a good study, they are of limited value and arguably useless to the subsequent interpretation of the single result that is observed. Therefore, while we require assurance that the study was well designed (pre-study power estimates), it is of little value to calculate power retrospectively. This arises from the logical inconsistency of applying pre-experiment probabilities which relate to a hypothetical group of results to a single result that is observed. The paper by Goodman and Berlin explains the problem in clear terms, and builds upon an analogy of 'trying to convince someone that buying a lottery ticket was foolish (the before experiment perspective) after they have hit the jackpot (the after-experiment perspective)'. Goodman and Berlin conclude 'avoid post hoc power estimates entirely', and recommend the use of confidence intervals and Bayesian estimates of treatment effects for study reporting. Two points are incontestable. Firstly, sample size and power calculations should always be carried out before the investigation commences, with reports stating how and why they chose that number of subjects to study. Secondly, there is little value in a post hoc calculation which takes the form of, for example, 'we observed a difference of 14% which was not significant; however, the power of detecting a difference of 14% or greater for our sample size would have been <50%'; it can be shown that such statements are tautological, and the post hoc power corresponding to a non-significant difference is always <50%! (Goodman, 1992) .
Confidence intervals for interpreing and reporting results
The problems of interpreting power calculations in the context of observed differences can be largely avoided by greater use of confidence intervals. Investigators often have prior beliefs concerning the results that they expect to observe, and when a difference is not statistically significant such beliefs may manifest themselves by comments such as 'the result was not significant because there was too little power to detect small differences'. While it may be true that the study had little power to detect a real difference of the magnitude of the observed one, the apparent implication that the observed difference is a reliable indicator of the magnitude of the real one is unfounded. Most tables for the number of patients in a log-rank test (e.g. Freedman, 1982; Machin and Campbell, 1987) assume that the patient acual is at a constant rate, so that the median kngth of follow up is equal to one-half the accual period plus the length of the post-accrual period (Freedman, 1982; Haybittle et al., 1990 Fwe I Sample szes required to detect survival differences P, -P2, for 90% power and 5% P-value. Also, the STO1 trial is an example of how even the most carefully planned trials may be based upon estimates which with hindsight are very suspect -even though they were based upon the best available information at the time the trial was designed. One might therefore be tempted to question the value of sample size estimation -is it ever possible to obtain meaningful estimates of sample size? Fortunately, however, this trial is in many ways atypical and has been deliberately chosen so as to highlight the potential problems.
Frequently there will be pnror information and past experience concerning baseline survival rates and the likely difference that might apply to the new treatment. As discussed below, when such information is not available, pilot studies may offer one way forward. Also, by calculating sample sizes for a variety of plausible baseline estimates and differences, it is possible to obtain an idea as to whether the proposed study is likely to be unrealistic.
In all cases, however, it is important to make the best estimate that one can when planning a trial; the points that we wish to emphasise in summary are that (a) it is futile to regard estimates of sample size as precise when there is so much uncertainty about the survival rates-they should be treated with caution and usually rounded upwards; (b) sensitivity analysis can be revealing at the design stage, and power implications should also be reviewed at later stages in the trial and when it is analysed; and (c) one should be circumspect about the whole procedure of estimating sample size. Despite these difficulties, however, it is essential to perform sample size calculations before the start of a tnral. steps and small trials will never be able to detect such differences. Small trials are therefore doomed to obtan misleading results, caiming 'no difference' even when a potentially very useful treatment advantage is in fact present. Furthermore, if a small trial does obtain a sign t Pvalue, the estimate of the treatment difference will almost certainly be an overestimate, often a gross overestimate, but with a wide confidence interval.
We hold a more mixed view. It is alvays preferable to aim for a trial that has a reasonable chance of obtaiing a meaningful result, that is to say a trial which has adequate power to detect the difference of interest. However, if this is not pracicable, we would accept that any trial is better than no trial, provided two conditions are met (1) All publications about the trial must make it clear that the power was low, and that the results can at best be regarded as hypothesis forming. Deeper interpretations cannot be place upon either sign or non-significance, even though the temptation is to be dismissive of non-sign ('What can one expect -the sample size was too small') and to attach too much importance to signifiance (in a small trial, lacking power, a value of P<5% will frequently indicate no more than that the trWial is among the 5% which one expects to return false-positive P-values).
(2) The trial, like all trials, should be registered before it is commenced (Fayers et (Chalmers et al., 1977; Pocock, 1983; Sacks et al., 1983; Gehan, 1984; Micciolo et al., 1985; Diehl and Perry, 1986 The advantage of an internal pilot is that it can be relatively lawrg -for example, half the anticipated patients -with no increase in time or money. It provides an insuance against misjudgement regarding the baseline assumptions. It is, however, important that the intention to conduct an internal pilot study is recorded at the outset and that full details are given in the study protocol; otherwise there may be suspicion that the invesugators performed multiple looks before deciding to make ad hoc changes to the protocol.
The theoretical implications of this approach are still being explored, but it would appear to place on a more scientific footing a procedure which one suspects has sometmes been instincvely yet covertly applied (and misapplied) Simon and Altman. 1994) . Also, as always with Cox models. sample size relates to the number of events observed and not the number of patients; if the event rate is low, the total number of patients must be increased accordingly. Simon and Altman (1994) . in an earlier editorial, have discussed statistical aspects of prognostic factor studies. As they note. when the sample size is too small, there are problems of multiplicity of testing which frequently result in potential predictor variables being declared significant by chance alone. The relative importance of the 'significant' factors will also be unreliable. Claims for the predictive accuracy of the prognostic equation are liable to be grossly overstated. That a small sample size is a real practical problem can be readily observed: if one compares the many published papers to be found describing prognostic factors within a single disease area, it is common to find major divergence of opinion as to the most useful factors -and even as to which is the most important single factor.
Very little work has been done upon formal methods of estimating sample sizes when evaluating prognostic factors, although various authors have suggested rules based upon intuition and experience. For example, Harrell et al. (1985) suggest that. with half the data set being used for 'training' and the other half reserved for subsequent validation of the prediction equation, then 'as a rough rule of thumb one should not attempt a stepwise (Cox) regression analysis when there are fewer than ten times as many events in the training sample as there are candidate predictor variables. The problems become more severe when one considers interaction terms in the mode.'
Alternatively. Fielding et al. (1992) suggest that the procedure for introducing a new candidate factor into existing prognostic models should be 'first ... the prognostic relationship will be evaluated in a study of several tens of patients (e.g.. 50-100). If the results appear promising ... the results will be studied on several hundreds of patients.' They also note that, after a statistical model has been developed, its validity should be verified from a separate data set; this requires yet more patients.
A paper by Schumacher et al. (1994) investigates the use of Cox models for evaluation of prognostic factors. They note that prognostic factors should exhibit large relative risks if they are to be useful, which might at first sight suggest that smaller numbers of patients are required. Practical experience combined with the results from their simulation studies lead them to suggest that 'studies with less than 25 events per factor cannot be considered as an informative and reliable basis for the evaluation of prognostic factors.' Furthermore, the relative risks and prevalence of each factor must be considered. They conclude that small studies can at best only serve to create exploratory hypotheses, and might lead to misleading confusion; the large studies that are necessary will often require collaboration between groups, or the use of meta-analyses.
Schumacher et al. also describe a formula for sample size when considering a single binary prognostic factor. However, prognostic factor studies invariably involve a number of factors, often including some with more than two levels. This necessitates using a general multivariate form of the simpler equation, and to solve this one would have to know the multivariate distribution of the prognostic factors in advance, which is not realistic (M Schumacher, personal communication). Thus, to a large extent one has to rely upon experience, supported by simulation and some theory for some typical situations.
Conclusions
Sometimes the estimation of sample size can be based upon precise requirements accompanied by detailed information about baseline rates and variability. Unfortunately, in our experience, such situations are rare. All too often in clinical trials and many other medical investigations there is a lack of prior knowledge about what to expect from the study, making sample size calculations fraught with difliculty. However, despite the attendant problems, the estimation of sample size and the consideration of power implications is of fundamental importance to the design of a sensible and realistic study and should always be undertaken with the greatest of care. Full details of the methods used to estimate sample size requirements should be recorded. We note with approval that Sampk size: hw many patent are necessary? PM Fayers and D Machin * 9 such information is increasingly demanded by funding bodies, independent protocol review committees, ethical review panels, and, at the conclusion of the study, journals to which reports are submitted.
Appenix A: Use of the nomogram The left scale gives the power of the log-rank test corresponding to P<O.O1 and P<0.05. The middle scale gives the total number of deaths or events that it is required to observe. The right scale shows the change in survival. presented as a percentage change in the median or as the hazard ratio. If a straight edge is placed over selected values on any two of the scales, the corresponding value may be read off the third one.
For example. suppose we wish to detect a change from a median survival of 10 months to a median survival of 15 months, and choose to use a power of 90% and a 5% P-value. The change in median survival corresponds to a 50% increase. Reading across the nomogram suggests that the appropriate sample size is 260 events, or 130 per treatment gronup. If a power of 80% is acceptable. a total of 180 events would be required. whilst for 90 0 power and a 60% increase in median survival just under 200 events are required.
Alternatively, if survival proportions x, and K2 are used instead of medians, the hazard ratio is given by h = log(ic) log(wr9. and this is also shown on the right-hand scale.
If x is the average survival proportion x = (Kl -K2) 2. then for e events the number of patients can be estimated by e (1 -K).
